Agreement Expands Partnership Between Cosmo Pharmaceuticals and Medtronic, Set to Transform Endoscopy with Cutting-Edge AI Technology Ad hoc announcement pursuant…
USE OF PARSORTIX SYSTEM IN PRE-CLINICAL MODEL UNLOCKS OPPORTUNITIES FOR DRUG DISCOVERYHarvested CTCs reveal gene expression profile associated with development…
POLB 001 - targeting Cytokine Release Syndrome (CRS) associated with cancer immunotherapiesLONDON, UK / ACCESSWIRE / December 11, 2023 /…
Reporting Complete Response Data from the Ongoing APTIVATE International Phase 1/2 Study of Tuspetinib (TUS) in Relapsed/Refractory AML PatientsTUS Single…
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetesAt…
A post hoc analysis of patients with higher transfusion burden at baseline showed a larger percentage of patients achieved transfusion…
Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of patients reporting ≥1…
Treatment adapted studies show the potential for MRD assessment to guide the personalization of blood cancer careNew data demonstrates MRD…
CHICAGO, IL / ACCESSWIRE / December 8, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…
Global experts gather at Cornell Tech, advancing early detection and survival in pancreatic cancer fightNEW YORK, NY / ACCESSWIRE /…